Please login to the form below

Not currently logged in
Email:
Password:

Cephalon

This page shows the latest Cephalon news and features for those working in and with pharma, biotech and healthcare.

Lundbeck challenge to EC pay-for-delay ruling fails

Lundbeck challenge to EC pay-for-delay ruling fails

Two other investigations - involving AstraZeneca/Nycomed and Teva/Cephalon - did not result in enforcement action by the Commission.

Latest news

  • US government probes Lilly and Merck over drug pricing US government probes Lilly and Merck over drug pricing

    In July both AstraZeneca (AZ) and Cephalon settled an action brought by the US government which accused them of underpaying. ... AZ paid nearly $47m to settle the cases, with Cephalon stumping up $7.5m, and at the time the DoJ said it would "continue to

  • Teva hit with $1.2bn pay-for-delay fine Teva hit with $1.2bn pay-for-delay fine

    Israeli-based Teva has reached a settlement resolving the Commission's antitrust suit charging its subsidiary Cephalon, with illegally blocking generic competition to its blockbuster sleep-disorder drug Provigil (modafinil). ... As part of the settlement,

  • Teva slapped with $512m fine on pay-for-delay deal Teva slapped with $512m fine on pay-for-delay deal

    Teva is paying $512m to settle a legal case against its subsidiary Cephalon used pay-for-delay tactics on its wakefulness drug Provigil (modafinil). ... cases. The lawsuit, originally filed in 2006 by drug wholesalers and retailers that buy directly from

  • EU hits Servier and generic firms with €428m 'pay-for-delay' fine EU hits Servier and generic firms with €428m 'pay-for-delay' fine

    Meanwhile, antitrust investigators in the EU are still looking at possible collusion between Teva and Cephalon, which is now owned by the Israeli company, concerning narcolepsy treatment Provigil (modafinil), while a

  • Global biosimilars market “will see exponential growth” Global biosimilars market “will see exponential growth”

    Biosimilar companies can reduce their market access time by linking with other companies with expertise in biosimilars manufacturing and development, Sashidhar added, citing Teva's alliance with Cephalon and Lupin Pharmaceuticals'

More from news
Approximately 1 fully matching, plus 83 partially matching documents found.

Latest Intelligence

  • Pharma deals in May 2015 Pharma deals in May 2015

    This has proved to be the case following Teva's purchase of Cephalon in May 2011 for $6.2bn which brought Provigil (modafinil for sleep disorders) into the portfolio.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 8 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics